Siemens Healthineers at ECR 2017Let's shape the future of healthcare together.

ECR 2017 - European Congress of Radiology
March 1st – 5th, 2017
Austria Center Vienna (ACV), Vienna, Austria
Expo X5, Entrance Level, booth #11

 

At this year’s ECR, we invite you to experience the pioneering spirit and engineering expertise of Siemens Healthineers. See how we enable healthcare providers worldwide to pioneer healthcare, while providing increased outcomes and reduce costs.

ECR 2017 trailer

Wednesday, March 1st
10:30 a.m. – 05:00 p.m., ACV 01, Studio 2017

What are the current discussions and trends in breast diagnostics?
Don’t miss the chance to be part of the Breast Care Day 2017 - the premiere event at ECR!
The perfect combination of the latest studies, daily practice and a future outlook with open discussions with leading experts:

  • The dense breast
  • Multimodality imaging
  • Trends in Breast MRI
  • Breast tomosynthesis and screening
  • Pitfalls with mimic and mask effects

Siemens Healthineers and Bayer Healthcare welcome you to the 7th Breast Care Day


Satellite Symposia ECR 2017

Wednesday, March 1st to Saturday, March 4th
12:30 p.m. – 01:30 p.m.

Discover the clinical and industry perspective from various innovations, including technical updates, emerging trends and future innovations. Join the Siemens Healthcare Satellite Symposia.

Right Dose

Reduce the risk of dose-related liability with dose management tools, reports, analyses and user trainings.


Right Dose Community

Share and discuss dose management strategies, settings, and protocols with other clinical experts.
Join the Right Dose Community1 and benefit from direct peer-to-peer exchange. The Right Dose Community is a user group within the Siemens Healthcare User Forum. This online space offers peer-to-peer clinical knowledge exchange as well as access to exclusive Siemens information.

Executive Alliance, Successful Health Business, health business strategies

Healthcare Executive Alliance fosters a continuous dialogue between you as a healthcare executive and Siemens Healthcare - together reflecting, substantiating, and implementing successful business strategies. As your partner, our aim is to help you succeed by turning your thoughts into actions that make a difference.

Breast Care Day

7th Breast Care Day at ECR on Wednesday, March 1st
10:30 a.m. – 05:00 p.m.
Location: ACV, First Level, Studio 2017

breast care day ecr 2017

What are the current discussions and trends in breast diagnostics?
Don’t miss the chance to be part of the Breast Care Day 2017 - the premiere event at ECR!
The perfect combination of the latest studies, daily practice and a future outlook with open discussions with leading experts:

  • The dense breast
  • Multimodality imaging
  • Trends in Breast MRI
  • Breast tomosynthesis and screening
  • Pitfalls with mimic and mask effects

Siemens Healthineers and Bayer Healthcare welcome you to the 7th Breast Care Day.

The participation is free of charge for all registered ECR participants

Chair:

J. Barkhausen; Lübeck/Germany

 


Preoperative breast MRI: first results from the MIPA study

F. Sardanelli; Milan/Italy

MIPA is an ongoing prospective observational multicenter study sponsored by Bayer, endorsed by EUSOBI and run by EIBIR/EuroAIM. Study was designed as an individual data analysis of two concurrent groups of women with a newly diagnosed first breast cancer, not candidate to neoadjuvant therapy, receiving or not receiving MRI before surgery. 

 In 2012, after an web-based call, 96 centres applied and 34 (19 academic) were selected from 14 countries; 28 started the enrolment. Up to July 2016, 4,944 patients were enrolled, 2,425 with complete eCRF: 1,201 (49.5%) without and 1,224 (50.5%) with MRI. Gadobutrol (0.1 mmol/kg) was used in 70% patients; 84% had also DWI. 

 A radiologist was involved in the MRI order in 68% of cases, a surgeon in 40%. Mastectomy rate planned after mammography/US was 185/1201 (15.4%) for non-MRI and 245/1224 (20.0%) for MRI-group (p<0.001). In MRI-group, 21 additional mastectomies (1.7%) were planned after MRI; bilateral surgery instead of bilateral was performed 13 (1.1%); of 1004 breasts conservatively treated after MRI, surgery was unchanged in 733 (73%), while a wider surgery or >1 excision wad done in 143 (12.5%) and a less extensive surgery was done in 128 (12.7%). Actual mastectomy rate was 192/1201 (16%) in non-MRI-group and 257/1224 (21%) in MRI-group (p<0.001; age/density-adjusted OR 1.4, 95% CI 1.3-1.6). Per-patient re-operation rate for close/positive margins was 135/1009 (13.4%) in non-MRI-group and 80/967 (8%) in MRI-group (p<0.001). These results show that already planned mastectomies prompt MRI, used as a confirmation tool, not vice versa and that MRI allows for tailoring conservative treatment.


First clinical experiences with a new 7ch breast imaging and biopsy coil

E. Wenkel; Erlangen/Germany

A new coil for high-resolution imaging of the breast at 3T is presented. Whereas most breast coils have a high number of coil elements for diagnostic purposes but only a subset can be used during biopsy, the 7ch BI Breast Coil has a special design to facilitate imaging with the full number of elements in the biopsy scenario, thereby offering comparable image quality to the imaging scenario.

Due to its open design, the coil is well suited for breast biopsy with lateral, medial and cranio-caudal access. Additional features like LED-lighting of the biopsy site simplify the workflow. During the presentation, first clinical cases and workflow experience with the new device are reported.


Gadolinium retention – impact on breast MRI?

J. Barkhausen; Lübeck/Germany

More than 30 years ago, contrast-enhanced MRI emerged as a new technique in clinical breast imaging and over the last three decades numerous clinical studies have shown excellent results for the detection and characterization of breast lesions. Despite the most recent improvement of high-resolution and diffusion-weighted MRI, dynamic contrast-enhanced sequences are still considered as key component of any breast MRI examination. The applied gadolinium-based contrast agents (GBCAs) were considered as very safe compounds until the association between nephrogenic systemic fibrosis and GBCAs was suspected in 2006.

Additionally, in late 2013 Kanda and colleagues described increased signal intensity in the dentate nucleus on unenhanced T1-weighted MR images as a consequence of repetitive previous GBCA administrations. Although no clinically relevant adverse events have yet been associated with the detection of gadolinium in the brain, the results of these studies must be taken seriously.

With respect to breast MRI, these issues are especially important for repetitive breast cancer screening in high-risk patients, for example, with BRCA mutations. In this lecture, the results of the most recent clinical trials addressing these topics will be presented in a comprehensive manner and the impact of these studies on daily clinical routine will be discussed.

Learning objectives:

  • To gain knowledge on the pharmacokinetics of different MR contrast agents
  • To discuss the potential risks of gadolinium based contrast agents
  • To learn about the most recent recommendations and guidelines.
     

Chair:

L.J. Pina Insausti; Pamplona/Spain

 


Dense Breast and how to overcome the radiologist’s “problem child”

L.J. Pina Insausti; Pamplona/Spain

In BI-RADS 2003, the composition was based on the overall density resulting in ACR category 1 ( <25% fibroglandular tissue), category 2 ( 25-50%), category 3 (50-75%) and category 4 (>75%). In BI-RADS 2013, the use of percentages is discouraged, because in individual cases it is more important to take into account the chance that a mass can be obscured by fibroglandular tissue than the percentage of breast density as an indicator for breast cancer risk. Four groups are used: a,b, c and d. The patterns c and d are considered as “dense”. Dense breasts reduce the sensitivity of mammography up to 50%. 

 This is the main limitation of mammography. Fortunately, tomosynthesis can significantly increase the sensitivity of mammography, especially if wide angle is used (increment of detection rate up to +43%). Tomosynthesis is able to reduce the superimposition of tissue and the anatomic noise, allowing the detection of occult lesions. However, at least a small amount of fat surrounding the lesion is needed to be detected. Breast US is widely used as an adjunct to mammography and it improves the sensitivity in dense breasts. 

 But US is a time-consuming, operator-dependent technique that detects too many benign lesions (false-positive results). This is why US cannot be used for population-based screening. MRI is not routinely used for the evaluation of dense breasts, although it can be very useful in some particular cases (preoperative planning, high-risk patients, etc.). 

 Learning objectives: 

  • To become familiar with the limitations of mammography in dense breasts 
  • To learn the role of Tomosynthesis to overcome the limitations of mammography in dense breasts 
  • To understand the role of breast US in dense breasts.

Volumetric breast density analysis in mammography and tomosynthesis – brief overview

H. Sartor; Lund/Sweden

High breast density is associated with an increased risk of breast cancer. However, qualitative measurements of breast density by radiologists may vary and be subjective. Automated VBDA was developed to provide objective and reproducible measurements. To explore the possibilities and clinical use of VBDA, previous studies have described the agreement between different methods of measuring volumetric density (e.g. by software such as Volpara and Quantra) and radiologists’ assessments in mammography (e.g. qualitative measurements such as BI-RADS and a visual analogue scale) with varying results.

DBT is a promising technique and a potential screening modality and the possibility to measure breast density on DBT images is important. Our group has previously compared breast density that was measured by radiologists to measurements obtained from an automated VBDA tool from Siemens using the central projection image in DBT. The results suggested that VBDA could be used in DBT in addition to mammography. Taken together, the use of a robust VBDA is important and seems possible in both mammography and DBT, enabling it to be used in individualised screening programs and in breast cancer risk scores.

Learning objectives:

  • To understand the clinical basics of volumetric breast density analysis (VBDA) based on previous studies
  • To acknowledge the difference between radiologists’ assessment of breast density and software measurements
  • To discuss VBDA’s potential use for mammography and digital breast tomosynthesis (DBT) in clinical practice

Current role of MRI in imaging of dense breast tissue

C. Van Gils; Utrecht/Netherlands

MRI is the most sensitive breast cancer imaging technique currently available and recommended for screening women with high breast cancer risk. Women with dense breasts have a moderately increased breast cancer risk. In addition, their dense tissue limits the detection of a tumour with mammography and, therefore, additional screening with MRI could provide a solution for these women as well. However, MRI is not included in screening recommendations for women with dense breasts.

The effects of MRI, and also those of other supplemental imaging methods, on breast cancer outcomes remain as yet unclear due to a lack of comparative studies with interval breast cancer rates, stage at diagnosis or breast cancer mortality as the outcome. In this presentation I will outline the present evidence for MRI screening in women with dense breasts, and indicate which type of evidence is still needed to proove its additional value.

DENSE, a large randomised controlled trial, that we are currently conducting, has been designed to deliver this proof. It investigates the value of additional MRI compared to usual screening practice, in women with extremely dense breasts and a negative digital mammography. Women are included solely on the basis of their breast density. A fully automatic and validated method is used to estimate mammographic density. The primary outcome is a difference in interval cancer rates between the two arms, the best proxy for a difference in breast cancer mortality.

Learning objectives:

  • To understand the current evidence for MRI screening in women with dense breasts
  • To learn what type of studies are needed to fully appreciate and weigh the benefits and harms of supplemental MRI screening in women with dense breasts

 


The future of breast cancer screening: where can it help the dense breast?

M. Golatta; Heidelberg/Germany

In most countries breast cancer screening is offered to women between (40)50 and 70(75). The organization of the screening programs differ from country to country, but in general every two or three years mammography is offered to the participating women. In the past years, several breast imaging techniques have been developed which have the potential to improve breast cancer screening. Digital breast tomosynthesis is one method that has been developed. Multiple low-dose images are obtained and digitally edited and reconstructed as a 3D-image of a breast.

The reconstructed 3D-image overcomes the weakness of standard mammography and enables reduction in false-positive findings as results of overlapping tissue. On the other hand, it also enables reduction in the false-negative findings in women with dense breast tissue. Studies have shown that combining ultrasound with mammography in screening settings can significantly improve the rate of found lesions. By adding US to the screening work flow the sensitivity can be improved especially in the dense breast. But US is very time consuming and the specificity goes down (more biopsies are necessary).

To overcome these two weaknesses, an “Automated breast volume scanner (ABVS)” and elastography can be used. Strain imaging ultrasound technology as Virtual Touch IQ (VTIQ) is a new method being used in breast ultrasound. Various studies have been able to show an increase of the diagnostic specificity without loss of sensitivity when combining the standard ultrasound BIRADS® classification with elastography. The improvement of the specificity will help to eliminate unnecessary breast biopsies in the future.

Learning objectives:

  • To become familiar with new breast imaging techniques
  • Breast cancer screening could be improved by embedding new breast imaging techniques like Tomosynthesis, US, Elastography, ABVS

Chair:

S. Heywang-Köbrunner; Munich/Germany

 


Is digital breast tomosynthesis ready for mammo screening?

S. Heywang-Köbrunner; Munich/Germany

For DBT, first systematic reviews of screening trials and of mostly retrospective data from the US confirm that DBT is clearly superior to mammography allowing significantly improved sensitivity. DBT leads to a slightly increased biopsy rate with comparable PPV compared to mammography screening with double reading. Unfortunately for a screening procedure, increased detection is not equivalent to mortality reduction, since increased detection could as well be caused by overdetection of "harmless“ malignancy (overdiagnosis).

So far no data on overdetection or mortality reduction exist for DBT. Even though important, they are generally difficult to obtain and require long-term follow-up. First indicators of effectiveness could include a significant reduction of interval cancers or an improved stage distribution of cancers detected during the follow-up round(s). Initial data on interval carcinomas are being published. However, first analyses show that evaluation of follow-up rounds remains essential. Thus, to date DBT remains the most promising new modality for screening.

Further data allowing estimates of effectiveness and potential overdiagnoses are needed and are gradually expected. Logistic problems (longer reading time, fatigue, optimised hanging protocols, comparison with DM or DBT priors, etc.) should be investigated as well as the potential of stratified DBT vs mammography screening.

Learning objectives:

  • To understand true benefits and risks of screening procedures
  • To understand present data on diagnostic accuracy and the gap concerning data on screening effectiveness and potential overdiagnosis
  • To understand logistic demands associated with future DBT screening
     

Experiences from the Malmö Breast Tomosynthesis Screening Trial

K. Lång; Malmö/Sweden

The Malmö breast tomosynthesis screening trial is a prospective population-based single-arm study including randomly invited women 40-74 years old eligible for the screening programme in the city of Malmö, Sweden. Women underwent one-view BT and two-view DM. The images were read and scored separately in a blinded double-reading procedure. Interim results of 7,500 women showed a significant increase in cancer detection rate (6.3 to 8.9/1,000) and recall rate (2.6% to 3.8%). The additionally detected cancers were mainly invasive, with a tendency of downstaging (Lång 2015).

Findings of stellate distortions simulating malignancy increased the false-positive rate with BT. The FP rate was reduced over time, suggesting a learning curve (Lång 2016). The BT images were acquired with reduced compression force which would be a great advantage for a new screening modality. Slabbing and reconstruction methods can be used to reduce the reading time and increase the image quality.

The main challenge of implementing BT in screening is the reading time (x 2-4) (Bernardi 2012, Skaane 2013). CAD and AI could provide a solution. Hopefully, attempts to implement BT in screening could be a catalyst towards the development of individualised screening programmes.

Learning Objectives:

  • To describe the Malmö Breast Tomosynthesis Screening Trial
  • To illustrate technical aspects of BT as a screening tool
  • To recognize the challenges of implementing BT in screening

Clinical performance of a synthetic mammogram (Insight 2D) and its role for screening procedures

M. Bernathova; Vienna/Austria


Practical challenges in screening with digital breast tomosynthesis

C. Van Ongeval; Leuven/Belgium

Chantal Van Ongeval, Julie Soens, Machteld Keupers, Cockmartin Lesley, Bosmans Hilde
University Hospitals Leuven, Leuven, Belgium

Learning objectives:

  • To evaluate the impact of the reading time on the use of digital breast tomosynthesis (DBT ) in breast cancer screening
  • To discuss the requirements of image transfer and data storage in breast cancer screening with DBT
  • Evaluation of additional tools in improving accuracy in reading of DBT in screening.

New tomo reconstruction algorithms – Clinical experiences

D. Uhlenbrock; Dortmund/Germany


Technical aspects of digital breasttomosynthesis

W. Lemish; Melbourne/Australia

There are a number of digital breast tomosynthesis (DBT) systems in the market that have applied differing technologies to acquire the data necessary for tomosynthesis image reconstruction. The various techniques all have advantages and some potential limitations. These differences could potentially produce different clinical outcomes and the lack of uniformity may make the comparisons between clinical trials difficult. We will review the principles of DBT and discuss the likely advantages and possible limitations of different methods available.

Learning Objectives:

  • To review the physical principles of Digital Breast Tomosynthesis
  • To become familiar with the strengths and limitations of different technologies used in Digital Breast Tomosynthesis.

Chair:
C. Van Ongeval; Leuven/Belgium

Breast MRI perspective:
E. Wenkel; Erlangen/Germany

Mammography/tomosynthesis perspective:
M. Bernathova; Vienna/Austria

Ultrasound perspective:
M. Golatta; Heidelberg/Germany

Benign or malignant lesion: the radiologist’s dilemma. This interactive session will discuss the use of ultrasound, mammography, tomosynthesis and MRI in cases of challenging benign and malignant findings.

The statements by Siemens' customers described herein are based on results that were achieved in the customer's unique setting. Since there is no "typical" hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption) there can be no guarantee that other customers will achieve the same results.

Looking forward seeing you at ECR 2017 in Vienna, Austria.

Symposia

Siemens Healthineers Satellite Symposia at ECR 2017
Wednesday, March 1 to Saturday, March 4, 2017

 

Join our multiple Satellite Symposia offered throughout the congress.

Satellite Symposium jointly organised by Siemens Healthineers and Bayer HealthCare

Satellite Symposium jointly organised by Bayer HealthCare and Siemens Healthineers

Chair:

J. E. Wildberger, Maastricht / Netherlands

Obtaining the optimal CT image the first time, every time: how to do it?

Ralf Bauer, St. Gallen, Switzerland

Tin Filtration CT: Clinical Applications and Evidence

Matthias May, Erlangen, Germany

CT 2 go: How mobility changes your daily business

Highlights

ECR 2017 - European Congress of Radiology
March 1st – 5th, 2017
Austria Center Vienna (ACV), Vienna, Austria
Expo X5, Entrance Level, booth #11

EXPO Halls X1, X2, X3, X4, X5 and Foyer D

 

Thursday, March 2 to Saturday, March 4

10:00–17:00

Sunday, March 5

10:00–14:00

Find out more about the products and solutions which Siemens Healthineers will feature at ECR 2017. We invite you to experience our pioneering spirit and engineering expertise and see how we enable healthcare providers worldwide to pioneer healthcare, while providing increased outcomes and reduce costs .

syngo RSNA 2016

Reading as it should be: simple and cinematic2

The new syngo.via1 enables you to read and report with ease: All your favorite tools are centralized in one place – from basic distance measurement to CT vascular tools, which saves you clicks and mouse movement. Don’t operate software, just read! And on top of that, the new syngo.via makes your communication with referrers and patients clear and convincing: With the new Cinematic VRT2, you can make your case look like something from an anatomy textbook. It only takes one click to create jaw‐dropping, easy‐to‐understand, clinical images.

1 syngo.via can be used as a standalone device or together with a variety of syngo.via-based software options, which are medical devices in their own right. syngo.via and the syngo.via based software options are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

2 Cinematic VRT is recommended for communication, education, and publication purposes and not intended for diagnostic reading.

SOMATOM go. Platform

Make success your daily business

The SOMATOM go. platform is built to address the needs of routine operations and beyond. Delivering high performance every day, opening doors to new clinical fields, and granting investment confidence, the SOMATOM go. platform will make success your daily business.

SOMATOM Drive

Drive precision for all

Regardless of who walks through the door, you are pressured to provide state-of-the-art CT imaging without compromising on image quality and precision. SOMATOM Drive, our latest Dual Source scanner, drives precision for your patients, your environment and business needs – every single moment.

Enterprise RSNA 2016

Provide value-based healthcare.

Demographic shift, growing chronic disease burdens, staff shortages, shifting to value-based reimbursement: strong trends are forcing a transformation in the healthcare sector – and IT solutions have to keep up. Backed by our long-term experience as an Imaging IT partner and innovation driver for healthcare enterprises, we support you in maximizing opportunities and minimizing the risks of today’s complex healthcare transformation.

Siemens Financial Services Healthcare

Making it easier to provide higher standards of care - Financial solutions for essential healthcare equipment.

We create value for our clients by employing a combination of technological and financial expertise. Our response to challenges in the healthcare system is best-in-class financing solutions. The financial experts from the Siemens Financial Services team will be at our stand to explain these to you in more detail.

Siemens Financial Services GmbH
Otto-Hahn-Ring 6
81739 Munich
Germany
Phone: +49 800 636-6360
E-Mail: info-sfl.sfs@siemens.com

teamplay

Connect, compare, collaborate.

teamplay is a cloud-based network that brings together healthcare professionals in order to advance medicine and human health. Make fast, well-informed decisions and optimize your workflows by connecting to up-to-date data, and collaborating with healthcare professionals worldwide.

Note: Please contact your Siemens representative whether teamplay is available in your country.

ARTIS pheno RSNA 2016

As individual as your patients

Engineered to be truly patient-oriented, ARTIS pheno® is a unique angiography system for individualized preprocedural planning, intraoperative guidance, and immediate assessment – regardless of patient condition or procedure complexity. It also helps keep the work environment clean at all times.

ARTIS pheno is pending 510(k) clearance, and is not yet commercially available in the United States or in other countries. Due to regulatory reasons, its future availability cannot be guaranteed.

syngo Embolization Guidance

Automatic detection. Targeted embolization

To be able to enhance the quality of life for your patients and maybe even downstage liver tumors, you need to know where the tumor and its feeding vessels are located. Our easy one-click syngo Embolization Guidance application automatically detects tumor-feeding vessels in the liver for targeted embolization – supporting you in performing an efficient and safe treatment.

syngo Embolization Guidance mentioned here is pending 510(k) clearance, and not commercially available in the US or in other countries.
Due to regulatory reasons, its future availability cannot be guaranteed.

Artis Freestyle Access Image

Complement your angio suite with wireless ultrasound capabilities

Artis Freestyle Access is a fully connected combination of an Artis with PURE® angiography system and an ACUSON Freestyle™ Elite ultrasound system.
It provides a zero cables, zero footprint, fully connected solution which greatly facilitates the use of ultrasound in the interventional workspace.

MIYABI Angio-CT

Powerful interplay.

The powerful interplay of a CT Sliding Gantry and an angiography system offers possibilities from interventional oncology to stroke and trauma cases.

High Definition Breast Tomosynthesis

Trust in what you see – at the widest angle.

Increase your diagnostic confidence efficiently and easily with High Definition Breast Tomosynthesis. Already superior with the widest angle, the highest number of projections, and full detector readout, it is now the world’s first tomosynthesis to incorporate EMPIRE Technology:

  • See tissue and lesions with unprecedented clarity
  • View microcalcifications clearly, and their morphology precisely
  • Get Insight, the first synthetic visualization of tomosynthesis in 2D and 3D
  • Reduce patient dose by replacing additional mammograms with Insight 2D
  • Gain new depth with Insight 3D, for you, your peers and your patients

1 High Definition Breast Tomosynthesis, EMPIRE Technology, Insight 2D and Insight 3D are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

Mammomat Inspiration

The reference in low dose mammography

Every woman has the right to the right dose! This is why PRIME Technology1 is standard on all new Mammomat Inspiration mammography systems.
The right dose is as low as possible without compromising image quality. PRIME Technology is the world's first software based antiscatter solution for mammography. Enabling up to 30% less dose2 without compromising image quality, PRIME is unique in achieving the right dose.

1 PRIME is for a maximum breast thickness of 70 mm under compression
2 Compared to grid-based acquisition with Mammomat Inspiration, depending on breast thickness.

syngo.Breast Care

2D & 3D mammography reading and advanced visualization

syngo.Breast Care1 is the client-server application for state-of-the-art 2D and 3D tomosynthesis reading including CAD display – wherever2 you are, even with simultaneous users. With the Link-it functionality, regions of interest in multiple views are matched. This helps you to speed up your decision making and to make a more confident diagnosis.

1 syngo.Breast Care is not commercially available in all countries. Due to regulatory reasons its future availability cannot be guaranteed. Please contact your local Siemens organization for further information.
2 Prerequisites include: Internet connection to clinical network, DICOM compliance, meeting of minimum hardware requirements, and adherence to local data security regulations

Cios Fusion

Fuse surgical versatility with Full View FD

Increase the competitiveness and surgical versatility of your institution by equipping your OR with innovative imaging technologies.

  • 160% more to see – with Full View FD1
  • Save time – with advanced table-side control2
  • Drive surgical revenue – with innovative technology

Cios Fusion is not commercially available in all countries. Due to regulatory reasons its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

1 Compared to today’s conventional 23 cm / 9 inch image intensifiers
2 Option

SOMATOM Confidence RT Pro - Image

Blaze a new trail in RT – Look closer. See further.
No more compromise between efficiency, patient satisfaction, and clinical outcomes. Face present and future RT challenges with confidence.

Multix Fusion Max Image

Built to perform

With Multix Fusion Max*, Siemens Healthineers offers a unique system concept combining consistent performance with intelligent cost-reduction solutions and fast, high quality results. Experience multiple gains in combination with other members of the MAX family.
 
*Multix Fusion Max is not commercially available in all countries. Due to regulatory reasons its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

The MAX effect

Where gains multiply

To address today’s radiologic needs, Siemens Healthineers has introduced MAX systems that cover the broadest range of applications in the market.
The combination of MAX systems generates the MAX effect – multiplying your benefits in standardization, savings, and satisfaction.

MAX systems are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

Mobilett Mira Max

Your mobile imaging companion

Mobilett Mira Max1 is a fully digital mobile X-ray machine that helps to speed up the examination workflow. It makes mobile X-ray imaging effortless and fast, and with its powerful generator and MAX detectors provides outstanding image quality in seconds.
 

*Mobilett Mira Max is not commercially available in all countries. Due to regulatory reasons its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

Multitom Rax

Join the new movement with robotic X-ray

Multitom Rax1 - the world’s first Twin Robotic X-ray scanner - uniquely combines patient care and productivity. Its Robotic Advanced X-ray technology (RAX) opens up a unique combination of high asset utilization, new clinical insights including natural Real 3D2 and less patient positioning and transfers. All in one room.

1 Multitom Rax is not commercially available in all countries. Due to regulatory reasons its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.
2 Option, only in combination with additional workstation syngo X workplace.

Strategic Planning Sessions

Get the most from your investment with customized solutions

The more transparency you have in all areas of your business, the better your patient outcomes. We at Siemens Healthineers want to enable you with valuable expertise by providing a flexible, efficient experience that exactly meets your needs. To help you achieve clinical excellence, greater operational efficiency, and financial sustainability, we would like to cordially invite you to your personal Strategic Planning Session at the Siemens Healthineers booth during this year’s ECR!

 

The products/features and/or service offerings (here mentioned) are not commercially available in all countries and/or for all modalities. If the services are not marketed in countries due to regulatory or other reasons, the service offering cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.

PEPconnect

Your smarter connection to knowledge

Improve your skills and qualifications following your schedule. Easily supervise and tailor everyone’s knowledge level – while keeping training costs down. And benefit from a competency-based education that provides a personalized learning experience for everyone. Discover PEPconnect, the education and performance experience from Siemens Healthineers.

 

The products/features and/or service offerings (here mentioned) are not commercially available in all countries and/or for all modalities. If the services are not marketed in countries due to regulatory or other reasons, the service offering cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.

LifeNet

eService portal for more control and less hassle

Whether you want to plan maintenance activities, monitor the status of your systems and service requests, or document service history: LifeNet is a web-based portal that lets you manage the performance and maintenance of all your Siemens Healthcare systems 24/7. With LifeNet, you are always on top of things – and keep calm whatever happens around you.

The products/features and/or service offerings (here mentioned) are not commercially available in all countries and/or for all modalities. If the services are not marketed in countries due to regulatory or other reasons, the service offering cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.

Videos from the booth

Get some live impressions of our ECR innovations.

We are looking forward to see you again in 2017.

The SOMATOM Drive with Dual Source technology is equipped with an automated voltage setting that is designed to allow individual kV selection to treat each patient according to their needs. Watch Ass.-Prof. Dr. Helmut Ringl, Medical University Vienna, Austria, gives some insights into our new CT scanner gained during research and development.

Easily manage and organize important health documents is saving you time and making your next appointment much more efficient. The new eHealth solution sense offers a physician portal, which supports cross-institutional treatment processes as well as self-service portal for patients, providing electronic health records on demand.

Today’s PACS are productivity tools to support your clinical goals. With syngo.plaza, you can benefit from software solutions for routine reading that increase quality and productivity in your radiology department. Watch the experiences of Dr. Andi Binaj, MD, Clinical Institute of Radiology, University Hospital Krems, Austria with syngo.plaza.

TwinBeam Dual Energy for single-source CT systems enables simultaneous imaging at two different energy levels. At ECR 2016 we talked to Dr. Bhavin Jankharia, Jankharia Imaging, Mumbai, India about how TwinBeam Dual Energy works and how he uses it in clinical routine.

Our universal imaging software for 3D reading and advanced visualization syngo.via offers a complete suite of molecular imaging applications for oncology, cardiology and neurology. Watch Anatoliy Kalinovskiy, Siemens Healthcare Molecular Imaging, explain the different applications of syngo.via for molecular imaging.

Our new SOMATOM Drive is designed to enable healthcare professionals to provide reliable diagnostic imaging across all clinical disciplines as well as a new quality of patient care. Ass.-Prof. Dr. Dr. Paul Apfaltrer, Medical University Vienna, Austria, provides some insights into our new CT scanner gained during the research and development phase.

Children are often not able to hold their breath long enough for a MRI scan. Our software FREEZEit intelligently resists motion artifacts and makes robust, free-breathing, and contrast-enhanced exams possible. Listen to Sonja Kinner, MD, and Haemi Schemuth, Essen University Hospital, Germany, talking about their experiences with FREEZEit.

Our Biograph mMR MR-PET system with E11 software is designed to set the pace in diagnostic imaging, by combining 3T MRI with proven molecular imaging, fully integrated in one system. Listen to Prof. Vicky Goh and Prof. Gary Cook, Kings College London, Great Britain, talking about the challenges and opportunities in MR-PET.

Our new SPECT/CT system offers two special features: xSPECT Bone for increased image quality and xSPECT Quant for accurate and reproducible quantification. These technologies support physicians in distinguishing between degenerative disease and cancer as well as leveraging automated quantification for therapy planning and early treatment modification.

Our cloud-based network teamplay gives healthcare professionals access to their data for faster decision-making based on reliable, well-structured and up-to-date information. Furthermore, it supports them in optimizing their imaging performance by providing insights into usage details such as number of patients and exams of particular modalities.

What if you could make real 3D diagnostic images of a patient with backache in standing position? Our new Twin Robotic X-ray scanner allows exams and diagnoses under natural weight-bearing, therefore opening up new clinical possibilities. Listen to Robyn M. Benz, MD, University Hospital Basel, Switzerland about her experiences with the new system.

How could you make a difference in diagnostic confidence, therapy planning and early treatment monitoring? Our PET/CT system with FlowMotion technology moves the patient smoothly through the system’s gantry, while continuously acquiring PET data. Therefore, it provides consistent quantitative accuracy throughout entire clinical images.

Simultaneous Multi-Slice (SMS) for brain imaging uses an innovative technique to acquire images simultaneously rather than sequentially – thereby making 2D imaging up to three times faster. Watch Associate Professor Dr. Gustav Andreisek, University Hospital Zurich, Switzerland, explain how clinical routine imaging can benefit from SMS.

Welcome a new dual source scanner in our CT family. With its two X-Ray tubes and detectors it is designed to enable healthcare professionals to provide reliable diagnostic imaging across all clinical disciplines at very low dose values. Watch Mark Woods, Siemens Healthcare, talking about the potential benefits for patients and users.

As the demand for value-based care continues to grow, healthcare providers are looking for ways to improve care while driving down long-term costs. Our Biograph Horizon gives you the flexibility to address a broad range of oncology, neurology and cardiac indications at low total cost of ownership, thus enabling high-quality care to more patients.

1